Iovance closes $172.5M offering; Veklury approved for Covid-19 patients with severe renal disease
Just a few days after pricing a $150 million public offering, Iovance has now closed with 15% more raised, thanks to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
